Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript
02:52am, Thursday, 29'th Jan 2026
Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and ear
Agenus to Host First 2026 Stakeholder Webcast
06:24pm, Tuesday, 20'th Jan 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Access--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access
AHMEDABAD, India and PENNINGTON, N.J., Jan. 15, 2026 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") is an innovation-led life-scie
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration wi
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Tuesday, 13'th Jan 2026
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
07:30am, Monday, 12'th Jan 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France's National Agency for Medicines and Health Products Sa
Short Interest in Agenus Inc. (NASDAQ:AGEN) Rises By 56.5%
01:19am, Monday, 29'th Dec 2025
Agenus Inc. (NASDAQ: AGEN - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 2,774,043 s
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
08:05am, Tuesday, 23'rd Dec 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
01:43am, Thursday, 04'th Dec 2025
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
04:01pm, Wednesday, 19'th Nov 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BATTMAN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on W
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affair
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
09:42am, Monday, 10'th Nov 2025
Agenus (AGEN) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $2.63 per share. This compares to a loss of $3.17 per share a year ago.
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
07:30am, Monday, 10'th Nov 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights includ
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
01:47pm, Wednesday, 05'th Nov 2025
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOTBAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financ
